conclusion
This study reports a case of sunitinib-induced TMA diagnosed based on clinical presentation and response to treatment. Sunitinib-induced TMA is an uncommon adverse effect of sunitinib therapy, But it can be deadly. Due to the increasing use of this drug in cancer treatment, Oncologists should be aware of life-threatening thromboembolic events associated with sunitinib so that prompt and appropriate intervention can be undertaken.